introduction
Mantle cell lymphoma (MCL) accounts for ∼5% of nonHodgkin's lymphomas (NHLs) and was identified as a particular aggressive NHL entity in the early 1990s [1] [2] [3] [4] . Given the aggressive natural history of MCL, intensive chemotherapy procedures with or without myeloablative chemotherapy followed by autologous stem cell transplantation (auto-SCT) has been evaluated both in prospective and retrospective studies. Indeed, Dreyling et al. [5] demonstrated that upfront combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) followed by auto-SCT can allow for longer disease control duration as compared with CHOP plus interferonalpha (IFN-α) maintenance therapy. In the latter study, the complete remission (CR) rate was 81% after auto-SCT as compared with 37% after CHOP plus IFN-α. In addition, the Nordic group showed that high-dose CHOP alternating with high-dose cytarabine combined to rituximab and followed by auto-SCT can yield superior results if compared with conventional chemotherapy without auto-SCT [6] . Thus far, the benefit of auto-SCT in MCL has been confirmed by several reports [7] [8] [9] [10] [11] [12] . The hyper-CVAD regimen (with or without rituximab) with or without autologous stem cell support has been also evaluated in untreated MCL patients and could achieve CR rate > 90% and 3-year overall survival (OS) rate ∼82% [13] . In addition to high dose therapy, the use of rituximab upfront or at time of relapse has also improved response rates in MCL and OS [14] . Lenz et al. [15] showed that CR rates with R-CHOP was superior to CHOP alone upfront. At time of first relapse, addition of rituximab to the fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen was also shown to be superior to FCM alone [16] . While in the auto-SCT setting, Tam et al. [17] confirmed that addition of rituximab upfront led to a longer disease control duration. Furthermore, a meta-analysis demonstrated that rituximab plus chemotherapy was superior to chemotherapy alone in MCL [14] . The use of rituximab as a preemptive treatment of relapse after auto-SCT has also been explorer [18] . More recently, a phase III trial conducted by the European MCL network showed that a rituximab maintenance followed R-CHOP improved OS [19] .
However, despite better understanding of MCL pathophysiology and improved OS [20, 21] , MCL remains an incurable disease and most patients will experience relapse. Results of salvage chemotherapies are probably insufficient to provide long-term disease control. In addition, because median age at time of diagnosis is 65-68 years, most patients are not eligible for conventional myeloablative allogeneic SCT.
Therefore, reduced-intensity conditioning allogeneic stem cell transplantation (RIC-allo-SCT) may represent an attractive strategy. Several reports showed the feasibility of RIC-allo-SCT in aggressive lymphoma [22] [23] [24] [25] [26] [27] [28] . Some studies underlined the efficacy of RIC-allo-SCT and demonstrated the potential efficacy of graft versus lymphoma effect whereas others reported disappointing results. However, only few studies addressed the issue of RIC-allo-SCT in the setting of MCL [17, 27, 29] . Thus, the place of RIC-allo-SCT in MCL remains questionable [30] . The present retrospective report analyzed the outcome of 70 heavily pretreated MCL patients who underwent salvage RIC-allo-SCT.
patients and methods

study design
This was a retrospective study carried out in 12 allo-SCT centers [University of Hamburg, Germany (n = 14); University of Nantes, France (n = 10); La Pitié-Salpétrière Hospital, Paris, France (n = 8); Chaim Sheba Medical Center, Israel (n = 8); University Hospital of Bordeaux (n = 7); University Hospital of Lille, France (n = 6); University Hospital of Montpellier, France (n = 6); University Hospital of Grenoble, France (n = 4); University Hospital of Clermont-Ferrand, France (n = 3); Necker Hospital, Paris, France (n = 2); University Hospital of Angers, France (n = 1) and Hôtel-Dieu Hospital, Paris (n = 1)], which examined the outcome of 70 consecutive MCL patients who received salvage RIC-allo-SCT in each individual center. The diagnosis of MCL was made by the local pathologist experts according to standard international recommendations at time of diagnosis. Informed consent from patients and donors was obtained according to institutional guidelines in accordance with the Declaration of Helsinki. Investigators were requested to report on MCL adult patients aged ≥18 years who underwent RIC-allo-SCT as salvage treatment. Indication for RIC-allo-SCT depended on each center's policy.
study definitions and statistical analysis
Clinical outcomes that were collected included demographic, disease and transplantation characteristics, graft versus host disease (GVHD) status, time to relapse and survival. Characteristics considered were recipient age, sex, disease remission status at time of RIC-allo-SCT, type of donor and RIC-allo-SCT characteristics (GVHD prophylaxis and stem cell source). An HLA-matched was defined by an identical A/B identity at the serologic level and DRB1 plus DQB1 identities at the molecular level.
CR was defined as the disappearance of all clinical, biological and radiological disorders related to lymphoma. Partial response (PR) was defined as a > 50% reduction of tumor burden. Progressive disease was defined by > 25% increase of tumor mass. Other cases were defined as stable disease (SD) [31] . Standard criteria were used for GVHD assessment [32] . Incidences of transplant-related mortality (TRM) and acute and chronic GVHD were calculated. Probabilities of OS and event-free survival original articles Annals of Oncology (EFS) were calculated using the Kaplan-Meier estimate. The log-rank test was used for univariate comparisons. All potential prognostic factors of the univariate analysis (P value ≤ 5%) were included in the multivariate analyses, using Cox proportional hazards. Cox proportional hazard models without any covariate adjustment were fit to calculate hazard ratios (HRs) and corresponding 95% confidence intervals (CIs). Cumulative incidence was calculated for TRM. All P values were two-sided; significance was set at the level of 5%. No adjustment was made for multiple comparisons. Statistical analyses were carried out using R software version 2.8.1.
results patients and transplant characteristics
Patients and transplant characteristics are summarized in Table 1 . A total of 70 MCL patients were included. Patients underwent RIC-allo-SCT from June 1999 to October 2008. All patients in this series presented with a refractory or relapsed MCL. The median number of previous lines of therapies was 2 (range, 1-5) including auto-SCT in 47 cases (a chemotherapy regimen followed by an auto-SCT is counted as one line). Prior chemotherapy regimens contained anthracyclines in 65 cases (94%), cytarabine in 59 cases (85.5%) and rituximab in 48 cases (69%). Eight patients (11%) received bortezomib. Median time from diagnosis to RIC-allo-SCT was 44 (range, 6-120 months). At time of transplantation, 55 patients were in CR or PR (of whom 35 patients in CR). HLA-identical sibling donors were used in 53% of cases. Various RIC regimen (n = 16) were used. Briefly, 66 patients received a fludarabine-containing regimen (94%). Twenty-six patients received busulfan plus fludarabine. Twelve patients received low-dose total body irradiation (TBI) and fludarabine. Five patients received fludarabine and cyclophospamide. Fifteen patients received fludarabine and melphalan including six patients who also received rituximab. In total, 15 patients received low-dose TBI (2 Gy), 25 (36%) received busulfan, 18 (26%) received melphalan and 11 (16%) received cyclophosphamide. Anti-thymoglobulin (ATG) was used as part of the RIC regimen in 43 cases (62%).
outcome In this series, eight patients (11%) failed to engraft. Venoocclusive disease (VOD) was reported in five cases including two patients with a previous history of auto-SCT. Among the five VOD patients, four have received a melphalan-containing regimen and four have received at least four lines of therapy before RIC-allo-SCT. Grade 3-4 acute GVHD was observed in 18 patients and 12 patients experienced extensive chronic GVHD. With a median follow-up of 24 (range, 1-103 months), 33 patients have died, of whom 21 were of TRM. The 1-and 2-year TRM rates were 22% (95% CI, 11-31%) and 32% (95% CI, 19-43%), respectively ( Figure 1A ). Disease status after RIC-allo-SCT could not be assessed in 12 patients because of early death. In the 58 assessable patients, 52 and 3 achieved CR and PR, respectively. The three remaining patients had SD or progressed after transplantation. The median EFS and OS were 18 and 27 months, respectively ( Figure 1B and C). At 2 years, the EFS and OS rates were 50% (95% CI, 39-55%) and 53% (95% CI, 42-68%), respectively.
statistical analyses for survival and TRM
The results of the statistical analysis are presented in Table 2 . The number of lines of previous treatments before RIC-allo-SCT had no impact on OS, EFS or TRM. No differences were observed between patients receiving a graft from an HLAidentical sibling or from an unrelated donor. However, there was a trend toward and increased incidence of grade 3-4 acute auto-SCT, autologous stem cell transplantation; RIC-allo-SCT, reducedintensity conditioning allogeneic stem cell transplantation; CR, complete remission; PR, partial remission; SD, stable disease; M, male; F, female; CMV, cytomegalovirus; P, positive; N, negative; PBSC, peripheral blood stem cell; BM, bone marrow; TBI, total body irradiation; ATG, antithymoglobulin; GVHD, graft versus host disease; CsA, cyclosporine; MTX, methotrexate; MMF, mycophenolate.
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GVHD when using an unrelated donor (P = 0.087, RR 0.12-1.16). Statistical analysis found no correlation between cGVHD and patient's outcome. A similar result was obtained for the subgroup of living patients after D100 (n = 58). OS and EFS were also not modified according to time of transplantation ( period 1999-2003 versus 2004-2008) . Among parameters evaluated for EFS, OS and TRM, only disease status at time of RIC-allo-SCT reached statistical significance in univariate analysis ( Figure 2) . Indeed, the 2-year EFS rates for CR, PR and SD/progressive patients were 62.5% (95% CI, 47-83%), 53% (95% CI, 35-80%) and 11% (95% CI, 19-66%), respectively. The 2-year OS rates for CR, PR and SD/ progressive patients were 62% (95% CI, 46-83%), 53% (95% CI, 34-81%) and 31% (95% CI, 13-73%), respectively. In univariate analysis, there was a trend for longer OS when patient did not receive ATG as part of the conditioning regimen (P = 0.11, Figure 3 ).
discussion
Long-term survival in patients with relapsed/refractory MCL remains poor, even after optimal salvage chemotherapy. Such poor outcome is the result of a higher rate of disease progression even after high-dose chemotherapy and auto-SCT. Selection of chemoresistant malignant clones after multiple chemotherapy regimens may explain relapse. Therefore, there is room for improvement in the management of patients with relapsed/refractory MCL. The current report assessed the outcome of 70 MCL patients who underwent RIC-allo-SCT as salvage therapy. Only few reports addressed the issue of RIC-allo-SCT in the specific setting of relapsed MCL. In this series, the 2-year EFS and OS rates were 50% and 53%, respectively. No plateau phase achieved at any time point after transplantation can question the existence of a graft versus MCL effect (GV-MCL). original articles
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However, there are other findings in the present report that support the existence of a GV-MCL effect and potential curative action of RIC-allo-SCT in refractory/relapsed. First, we observe a trend showing that the use of ATG increases the risk of relapse. One explanation is that ATG eradicates T cells and, thus abrogates the GV-MCL [33, 34] . The use of ATG can also explain why < 30% of our patients experienced cGVHD as compared with 50-60% in other reports [17, 27] . Interestingly, we observe a trend of a plateau phase in the group of patients who did not received ATG (see Figure 3A and B). A longer follow-up is necessary before to confirm this trend. Second, it is interesting to notice that the outcome after RIC-allo is not related to the number of previous lines of chemotherapy. This suggests that the immune mediated allogeneic GV-MCL effect imparted by RIC-allo-SCT may provide an alternative noncross-resistant mechanism that can eradicate chemo-resistant residual MCL cells. Indeed, the 3-year EFS for the 47 patients who relapsed after autologous is 48.7% (95% CI, 33.5-71%). The favorable impact of RIC-allo has also been reported by other groups. Recently, Tam et al. updated the M. D. Anderson's experience using RIC-allo-SCT for MCL with a long-term follow-up [17, 29] . This study confirmed previous reports from the same group showing that the number of lines of prior therapy was a major determinant for EFS only if patients had received more than five lines of prior therapies, a situation which was not encountered in our series. The latter highlights the potential for selection bias in singlecenter series and underscores the need for multicenter comparative trials in order to define the optimal salvage treatment strategy in MCL. In the M. D. Anderson's experience, the 6-year PFS rate was 46%, with a plateau phase achieved after 3 years and no relapse beyond 63 months of follow-up. Interestingly, most of the patients reported by the M. D. Anderson group received an RIC regimen containing fludarabine, cyclophosphamide and rituximab, raising the question of the role of rituximab as part of the RIC regimen for long-term disease control as already shown in follicular lymphoma [35] . In the Seattle's experience in relapsed/ refractory MCL patients, using fludarabine and low-dose TBI (2 Gy), the 2-year OS and disease-free survival rates were 65% and 60%, respectively. As shown in our analysis, disease status at time of transplantation was also highly predictive for outcome in the Seattle series [36] . Taken together, disease status at time of transplantation is likely the major determinant OS, overall survival; EFS, event-free survival; TRM, transplant-related mortality; HR, hazard ratio; CI, confidence interval; RIC-allo-SCT, reduced-intensity conditioning allogeneic stem cell transplantation; CR, complete remission; PR, partial remission; BM, bone marrow; PBSC, peripheral blood stem cell; M, male; F, female; CMV, cytomegalovirus; TBI, total body irradiation; ATG, anti-thymoglobulin; GVHD, graft versus host disease and NS, not significant. Only results with a P value < 0.2 are listed.
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for outcome in the setting of RIC-allo-SCT for MCL. The type of RIC regimen may also be one major parameter. Despite a relatively high number of patients, the multicenter nature of our analysis might explain some of the discrepancies observed between our results and those of the M. D. Anderson and the Seattle groups. An inherent difficulty in interpreting the disparate results between individual reports lies with the heterogeneity of the studies (single-center versus multicenter and cooperative group versus registry studies), the heterogeneity of the patients studied, the variation in the RIC procedure itself (e.g. the conditioning regimen and GVHD prophylaxis) and the duration of follow-up. Indeed, we failed to collect some items about patient's characteristic at time of diagnosis (like morphological variant, bulky disease, Mantle International Prognostic Index score … ) that could have potentially influenced patient's outcome. There is an almost universal consensus, however, that disease status at time of allo-SCT is a major determinant of response to RIC-allo-SCT, with chemorefractory patients experiencing significantly inferior survival rates because of poor disease control and an increased TRM. This is illustrated by the study from Robinson et al. reporting multicenter data from the EBMT in 22 MCL cases, and showing a 1-year TRM rate of 46% [28] . In the initial EBMT report, all patients relapsed within 2 years followed transplantation. The update of the EBMT study included 180 MCL patients, the 5-year PFS was 25% and 1-year TRM was 32% [37] . The British experience has also recently been published [27] . The study included 70 patients. The PFS at 5 years was only 37% with 18 patients who died because of MCL. Though, the results of the current study and those of other large studies support the ongoing exploration of RIC-allo-SCT in the treatment of patients with relapsed MCL. original articles
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However, the continuous incidence of disease relapse after RIC-allo-SCT remains an issue and the TRM remains too high. Several options may enhance these results. One option would be to avoid the use of ATG which not only reduces GVHD but also abrogates the graft-versus-lymphoma effect. The use of alemtuzumab in the conditioning regimen causes also deep depletion of T cells that reduces the GV-MCL, and thus increases risk of relapse [38, 39] . This finding in MCL and NHLs is in accordance with other reports that addressed the question of RIC-allo-SCT in chronic lymphocytic leukemia [40, 41] . An other option would be the administration of prophylactic donor lymphocytes infusions (DLIs) as it has been showed that DLIs can eradicate residual MCL cells [42] . Minimal residual disease (MRD) monitoring after allo-SCT could thus be very useful to decide of a preemptive relapse treatment by DLIs. In addition, results of MRD monitoring carried out at key time points during the course of the treatment may also be of great interest to select high-risk of relapse patients for whom a conventional chemotherapy treatment will not be sufficient to eradicate the disease. The European MCL network showed that CR patients who do not reach MRD negativity at the molecular level after auto-SCT are highly exposed to relapse. Therefore, MRD + patients at least at end of treatment could be good candidates for alternative therapeutic options including RIC-allo-SCT [43] . Rituximab in the conditioning regimen or its use early after RIC-allo-SCT may represent another attractive modality toward decreasing the incidence of disease relapse with little, if any, toxicity. Interestingly, the European MCL network reported a phase III prospective study that demonstrated the advantage for OS of a rituximab maintenance followed R-CHOP [19] . Bortezomib or lenalidomide which have demonstrated efficacy as single agent in relapsed/refractory MCL may also be an attractive option for a post RIC-allo-SCT strategy [44] [45] [46] . Indeed, the ultimate objective of RIC-allo-SCT is the achievement of long-term disease control without undue TRM. The issue of tolerability of a treatment strategy such as RIC-allo-SCT is of major importance in a disease setting in which the median age at diagnosis is usually older than 60 years, and patients being heavily pretreated, including those who had failed previous auto-SCT. In all, we conclude that data from this study provides further insight into the feasibility and efficacy of RIC-allo-SCT in MCL. The described results can lay the groundwork for prospective trials aiming to determine the exact role of RIC-allo-SCT in MCL. Moreover, these results are expected to be further improved with strategies aiming to enhance the immune effect without enhancing GVHD. A risk-adapted strategy combining with close minimal residual disease monitoring may also help selecting those MCL patients who will most benefit from RIC-allo-SCT. acknowledgements SLG and MM would like to thank the 'Région Pays de Loire', the Institut National du Cancer (INCa), the 'Association pour la Recherche sur le Cancer (ARC)', the 'Fondation de France', the 'Fondation contre la Leucémie', the 'Agence de Biomédecine', the 'Association Cent pour Sang la Vie' and the 'Association Laurette Fuguain' for their generous and continuous support for our clinical and basic research work. We thank the nursing staff for providing excellent care for the patients. 
